infliximab
Evolving Treatment of HS
Dr. Sayed presented an overview of treatment options for hidradenitis suppurativa (HS) and reviewed ongoing clinical trials. The landscape of treatment for HS is rapidly changing. Dr. Sayed predicts that many more treatment options will become available in the next 5–10 years. First, Dr. Sayed described current HS treatment options, including adalimumab, infliximab, golimumab, and…
Caring for the Patient with Cutaneous Immune-Related Events
Dr. Chen presented new research on the management of dermatologic immune-related adverse events (D-irAEs), including high-yield tips, and discussed potential future implications and therapeutic care of patients who receive immune checkpoint inhibitors (ICIs).